SOLIGENIX, INC.

Insider Trading Arrangements and Policies

During the quarter ended June 30, 2025, no directors orofficers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Transition of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 11, 2025, Richard Straube, MD, age 73, retired from his employment as Chief Medical Officer and Senior Vice President of Soligenix, Inc. (the “Company”) effective August 12, 2025. Also on August 11, 2025, the Company and Dr. Straube entered into a one-year consulting agreement (the “Consulting Agreement”), pursuant to which Dr. Straube will serve as the Company’s Consulting Chief Medical Officer effective August 16, 2025.

Dr. Straube has been with the Company since January 2014, when he initially became the Company’s Chief Medical Officer and Senior Vice President. He is a board-certified pediatrician with over 35 years’ experience in both academia and industry, including clinical research experience in host-response modulation. Dr. Straube received his medical degree and residency training at the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship at the University of California, San Diego (“UCSD”), and as a Milbank Scholar completed training in clinical trial design at the London School of Hygiene and Tropical Medicine. While on the faculty at the UCSD Medical Center, his research focused on interventional studies for serious viral infections.

The Consulting Agreement provides that Dr. Straube will be an independent contractor and will receive an hourly consulting fee of $1,000 per hour for up to ten hours per month of consulting work. The term of the Consulting Agreement may be extended by successive periods of three months by mutual agreement of the Company and Dr. Straube.

The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the Consulting Agreement, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.